Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

被引：47
|
作者：
Kudo, Masatoshi [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan
来源：
LIVER CANCER | 2022年 / 11卷 / 05期
关键词：
Atezolizumab plus bevacizumab; Hepatocellular carcinoma; ABC conversion; Curative therapy; Cancer-free status; Drug-free status; POSITRON-EMISSION-TOMOGRAPHY; T-CELL RESPONSES; RADIOFREQUENCY ABLATION; F-18-FDG PET/CT; TUMOR; LENVATINIB; DIFFERENTIATION; IDENTIFICATION; ENHANCEMENT; MULTICENTER;
D O I：
10.1159/000526163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：399 / 406
页数：8
相关论文
共 50 条
  • [21] Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
    Kinami, Takahiro
    Uchikawa, Shinsuke
    Kawaoka, Tomokazu
    Yamasaki, Shintaro
    Kosaka, Masanari
    Johira, Yusuke
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Yamaoka, Kenji
    Fujii, Yasutoshi
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Miki, Daiki
    Tsuge, Masataka
    Oka, Shiro
    CANCER MEDICINE, 2024, 13 (05):
  • [22] The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
    Shimose, Shigeo
    Saeki, Issei
    Ito, Takanori
    Takeuchi, Yasuto
    Tani, Joji
    Tomonari, Tetsu
    Sasaki, Ryu
    Sasaki, Kyo
    Kakizaki, Satoru
    Hatanaka, Takeshi
    Iwamoto, Hideki
    Tanabe, Norikazu
    Yamamoto, Takafumi
    Naganuma, Atsushi
    Shirono, Tomotake
    Kanayama, Yuki
    Nishina, Sohji
    Takayama, Tetsuji
    Kobara, Hideki
    Otsuka, Motoyuki
    Kawashima, Hiroki
    Takami, Taro
    Kawaguchi, Takumi
    Hepatology InVestigator Experts Japan HIVE-J Study Grp
    HEPATOLOGY INTERNATIONAL, 2025,
  • [23] Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
    Maesaka, Kazuki
    Sakamori, Ryotaro
    Yamada, Ryoko
    Tahata, Yuki
    Imai, Yasuharu
    Ohkawa, Kazuyoshi
    Miyazaki, Masanori
    Mita, Eiji
    Ito, Toshifumi
    Hagiwara, Hideki
    Yakushijin, Takayuki
    Kodama, Takahiro
    Hikita, Hayato
    Tatsumi, Tomohide
    Takehara, Tetsuo
    HEPATOLOGY RESEARCH, 2022, 52 (03) : 298 - 307
  • [24] Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Zheng, Yitao
    Xiang, Yanjun
    Shi, Hongqi
    Lin, Zhuoqun
    Cheng, Shuqun
    Zhu, Jiuting
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1079 - 1093
  • [25] Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma
    Yamaba, Shinpei
    Imai, Yukinori
    Sugawara, Kayoko
    Uchida, Yoshihito
    Fuchigami, Akira
    Uchiya, Hiroshi
    Nakayama, Nobuaki
    Mochida, Satoshi
    PLOS ONE, 2024, 19 (04):
  • [26] Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma
    Matsui, Teppei
    Nagai, Hidenari
    Mukozu, Takanori
    Wakui, Noritaka
    Matsuda, Takahisa
    Igarashi, Yoshinori
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (06) : 1058 - 1066
  • [27] LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
    Llovet, J. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Madoff, D. C.
    Finn, R. S.
    Ogasawara, S.
    Ren, Z.
    Mody, K.
    Li, J. Jing
    Siegel, A. B.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S702 - S703
  • [28] Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
    Arizumi, Tadaaki
    Ueshima, Kazuomi
    Minami, Tomohiro
    Kono, Masashi
    Chishina, Hirokazu
    Takita, Masahiro
    Kitai, Satoshi
    Inoue, Tatsuo
    Yada, Norihisa
    Hagiwara, Satoru
    Minami, Yasunori
    Sakurai, Toshiharu
    Nishida, Naoshi
    Kudo, Masatoshi
    LIVER CANCER, 2015, 4 (04) : 253 - 262
  • [29] TACE it or leave it: hard choices for intermediate-stage hepatocellular carcinoma patients beyond perfect health
    Peck-Radosavljevic, Markus
    LIVER INTERNATIONAL, 2010, 30 (01) : 3 - 4
  • [30] ACHIEVEMENT OF COMPLETE RESPONSE AND DRUG-FREE STATUS BY ATEZOLIZUMAB PLUS BEVACIZUMAB COMBINED WITH LOCOREGIONAL THERAPY IN PATIENTS WITH TRANSARTERIAL CHEMOEMBOLIZATION-UNSUITABLE, INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA: A MULTICENTER PROOF-OF-CONCEPT STUDY
    Kudo, Masatoshi
    Aoki, Tomoko
    Ueshima, Kazuomi
    Tsuchiya, Kaoru
    Morita, Masahiro
    Chishina, Hirokazu
    Takita, Masahiro
    Hagiwara, Satoru
    Minami, Yasunori
    Ida, Hiroshi
    Nishida, Naoshi
    Ogawa, Chikara
    Tomonari, Tetsu
    Nakamura, Noriaki
    Kuroda, Hidekatsu
    Takebe, Atsushi
    Takeyama, Yoshifumi
    Hidaka, Masaaki
    Eguchi, Susumu
    Chan, Stephen Lam
    Kurosaki, Masayuki
    Izumi, Namiki
    HEPATOLOGY, 2023, 78 : S1802 - S1803
12345